Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes

Chinese Medical Journal

Volumn 123, Issue 1, 2010, Pages 108-110

  Xu, Wei Lai ^a   Jin, Jie ^a   Qian, Wen Bin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

High intensity chemotherapy; Homoharringtonine; Induction; Myelodysplastic syndromes

Indexed keywords

ACLARUBICIN; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; IDARUBICIN; MITOXANTRONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LOW DRUG DOSE; MAINTENANCE THERAPY; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REMISSION; SURVIVAL TIME; TREATMENT DURATION;

ACLARUBICIN; ADULT; AGED; CYTARABINE; DRUG COMBINATIONS; FEMALE; HARRINGTONINES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74749097756     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.01.020     Document Type: Article

References (16)

1. Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005; 19: 767-775.
2. Wang XQ, Chen ZX, Chen SC, Lin GW, Ji MR, Liang JY, et al. Prognostic analysis of refractory anaemia in adult myelodysplastic syndromes. Chin Med J 2008; 121: 1787-1791.
3. Fukumoto JS, Greenberg PL. Management of patients with higher risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2005; 56: 179-192.
4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
5. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia (AML)) on outcome of AML-type chemotherapy. Blood 1997; 90: 2969-2977.
6. Cephalotaxus Research Coordinating Group. Cephalotaxine esters in the treatment of acute leukemia: A preliminary clinical assessment. Chin Med J 1976; 2: 263-272.
7. Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 2006; 20: 1361-1367.
8. Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 1999; 10: 40-42.
9. O?Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86: 3322-3326.
10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
11. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
12. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
13. Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001; 92: 1999-2015.
14. Faderl S, Kantarjian HM. Novel therapies for myelodysplastic syndromes. Cancer 2004; 101: 226-241.
15. Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006; 24: 5358-5365.
16. Irons RD, Wang X, Gross SA, Bao L, Ryder J, Chen Y, et al. Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications. Leuk Res 2006; 30: 769-775.